Search Results
Your search for The ,The matches 34725 pages
Showing 14701 - 14750Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer
On July 30, 2019, darolutamide was approved for the treatment of patients with nonmetastatic castration-resistant prostate cancer.1,2 Approval was based on findings in the double-blind phase III ARAMIS trial (ClinicalTrials.gov identifier NCT02200614), in which 1,509 patients were randomly assigned ...
Tumor Size and Grade Matter, and Ovarian Ablation by Chemotherapy May Explain Subgroup Anomaly in TAILORx
At the 2019 ASCO Annual Meeting, and simultaneously in The New England Journal of Medicine, we heard the third paper reporting results from TAILORx.1,2 The first, in 2015,3 indicated that women with node-negative breast cancers with Oncotype DX recurrence scores less than 11 did extremely well...
Pelotonia Institute for Immuno-Oncology Launched at The Ohio State University Cancer Center
THE OHIO STATE UNIVERSITY Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC– James) announced the formation of the Pelotonia Institute for Immuno-Oncology (PIIO), a comprehensive bench-to-bedside research initiative focused on harnessing...
Dana-Farber Researchers Win Grand Challenge Funding From Cancer Research UK
DANA-FARBER CANCER INSTITUTE researchers are Grand Challenge winners for a project that aims to discover how certain microbes inside the body lead to colorectal cancer and influence a patient’s response to treatment, Cancer Research UK announced recently. Dana-Farber Cancer Institute’s Matthew...
Expert Point of View: Carla S. Fisher, MD
CARLA S. FISHER, MD, Medical Director of Breast Surgical Oncology and Associate Professor of Surgery at Indiana University School of Medicine, Indianapolis, commented on the study that sought to identify HER2- positive patients who do, and do not, need surgery after neoadjuvant chemotherapy. “As...
Novel Treatments Under Study in Renal Cell Carcinoma and Prostate Cancer
There were numerous notable presentations at the 2019 Genitourinary Cancers Symposium, many of which were covered in The ASCO Post over the past few months. To add to our continued coverage of this meeting, here are some highlights from studies focusing on novel therapeutics in renal cell carcinoma ...
Can Some Women With HER2-Positive Breast Cancer Forgo Surgery?
Breast cancer researchers at The University of Texas MD Anderson Cancer Center, Houston, are beginning to select patients with HER2-positive breast cancer who might forgo surgery after neoadjuvant chemotherapy. While this fine-tuning is currently intended to inform clinical trials—in particular, to ...
Selinexor in Relapsed or Refractory Multiple Myeloma
In the Clinic provides overviews of novel hematology and oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On July 3, 2019, the oral nuclear export...
Virtual Reality May Improve Pain, Vision, Functioning in Patients With Cancer
Virtual reality can be used to improve functioning in patients with cancer, according to David Rhew, MD, Chief Medical Officer, Vice President and General Manager of Enterprise Healthcare, Samsung Electronics America. Research has shown that this technology can decrease pain and improve vision, as...
Polypharmacy Associated With Functional Decline in Older Patients With Advanced Cancer
Polypharmacy (ie, the concurrent use of eight or more medications) and potentially inappropriate medications may be associated with functional impairment in older adults with advanced cancer, according to research presented by Mostafa Mohamed, MBBCh, at the Multinational Association of Supportive...
FDA Clears Next-Generation Scalp-Cooling Device
ON JUNE 27, 2019, the U.S. Food and Drug Administration (FDA) granted clearance of the DigniCap Delta scalp-cooling system to Dignitana, for use by health-care providers in the United States. The device is a fourth generation of the DigniCap scalp-cooling system. It is indicated to reduce the...
FDA Approves Pexidartinib for Tenosynovial Giant Cell Tumor
ON AUGUST 2, the U.S. Food and Drug Administration (FDA) granted approval to pexidartinib (Turalio) capsules for the treatment of adult patients with symptomatic tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not responsive to improvement with surgery. ...
FDA Approves Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer
ON JULY 30, the U.S. Food and Drug Administration (FDA) approved darolutamide (Nubeqa) for the treatment of nonmetastatic castration-resistant prostate cancer. Approval was based on the ARAMIS study, a multicenter, double-blind, placebo-controlled clinical trial of 1,509 patients with nonmetastatic ...
Opioids for Cancer Pain: A Review of the Evidence and Current Challenges
In the wake of the opioid crisis in the United States, patients with cancer pain are often undeservedly confronted with rigid barriers to receiving the opioids they need. To compound this problem, the research around opioids in cancer pain has been limited—placebo-controlled trials are lacking,...
CMS Finalizes Decision to Cover CAR T-Cell Therapy for Medicare Beneficiaries
ON AUGUST 7, the Centers for Medicare & Medicaid Services (CMS) finalized the decision to cover U.S. Food and Drug Administration (FDA)-approved chimeric antigen receptor (CAR) T-cell therapy among recipients of Medicare benefits. FDA-approved CAR T-cell therapies are approved to treat patients ...
Optimal First-Line Therapy for Stage IV Non–Small Cell Lung Cancer: Immunotherapy Alone or With Chemotherapy?
Recent studies in non–small cell lung cancer (NSCLC) have shown benefit for combining checkpoint inhibitors with chemotherapy. Should combinations, therefore, be the first choice for treating patients with newly diagnosed stage IV disease? Two lung cancer experts debated this point at the 2019...
All Oncologists Are Geriatric Oncologists...They Just Don’t Know It Yet
You don’t have to be a geriatrician to properly evaluate and manage older patients with cancer. The wave of older patients with cancer predicted over 30 years ago is now fully upon us. The oncology community finds itself ill-prepared to manage the increased number of older patients. It is not just...
Expert Point of View: Thomas Paul Slavin, Jr, MD
Thomas Paul Slavin, Jr, MD, of City of Hope National Medical Center, where he is Assistant Clinical Professor in the Department of Medical Oncology, Division of Clinical Cancer Genomics, and a Program Member of Cancer Control and Population Sciences, commented on these substudy findings. The...
Exploratory Analysis Shows DNA Methylation Assay Highly Specific for Cancer Detection
A cell-free DNA test based on the presence of DNA methylation has proven highly specific as a multicancer detection test and appears especially good at detecting high-risk malignancies. In most cases, it can also accurately pinpoint the tumor’s tissue of origin, researchers reported at the 2019...
FDA Pipeline: Priority Reviews in Prostate Cancer, Mantle Cell Lymphoma
This week, the U.S. Food and Drug Administration (FDA) accepted new drug applications for enzalutamide in metastatic hormone-sensitive prostate cancer and zanubrutinib in relapsed or refractory mantle cell lymphoma, and granted both applications Priority Review. Priority Review for Enzalutamide in ...
Genomic Landscape of Merkel Cell Carcinoma
Researchers have developed the largest descriptive genomic analysis of patients with Merkel cell carcinoma to date. Their analysis, published by Knepper et al in Clinical Cancer Research, will provide important information to improve the care and treatment of patients with Merkel cell...
Addition of Pemetrexed/Carboplatin to Gefitinib in Advanced EGFR-Mutant NSCLC
In an Indian single-center phase III trial reported in the Journal of Clinical Oncology, Noronha et al found that the addition of pemetrexed/carboplatin to gefitinib improved progression-free and overall survival in first-line treatment of advanced EGFR-mutant non–small cell lung cancer...
Swallowing-Related Quality of Life After Radiotherapy vs Surgery for Oropharyngeal Squamous Cell Carcinoma
In the phase II ORATOR trial reported in The Lancet Oncology, Nichols et al found a statistical but not clinically meaningful improvement in swallowing-related quality of life outcomes 1 year after treatment with radiotherapy vs transoral robotic surgery and neck dissection in patients with...
What Causes Liver Injury During Treatment With Pembrolizumab
Immunotherapy as a treatment for advanced solid cancers has rapidly evolved over the past decade—often yielding remarkable results. However, its use has also given way to new adverse effects, including drug-induced gastrointestinal and liver toxicities. “Checkpoint inhibitors are a game changer...
USPSTF Recommendation on Screening for Pancreatic Cancer in Asymptomatic Adults
As reported in JAMA, the U.S. Preventive Services Task Force (USPSTF), in a reaffirmation of its 2004 recommendation, has recommended against screening for pancreatic cancer in asymptomatic adults (a grade D recommendation).1 In developing the current recommendation, the USPSTF reviewed evidence on ...
Adjuvant Chemoradiotherapy vs Radiotherapy Alone in High-Risk Endometrial Cancer
As reported in The Lancet Oncology by Stephanie de Boer, MD, and colleagues, a post hoc updated survival analysis of the phase III PORTEC-3 trial has shown a significant overall survival benefit of adjuvant chemoradiotherapy vs radiotherapy alone in women with high-risk endometrial cancer. A...
Long-Term Follow-up of Patients With Melanoma, Kidney Cancer, and Lung Cancer Receiving Nivolumab
As reported by Suzanne L. Topalian, MD, and colleagues in JAMA Oncology, long-term follow up of patients from a phase I expansion cohort study indicated 5-year overall survival rates of 34.2%, 27.7%, and 15.6% among patients who received nivolumab monotherapy for advanced melanoma, renal cell...
5-Year Follow-Up of KEYNOTE-006 Trial of Immunotherapy Regimens in Advanced Melanoma
In a post hoc 5-year follow-up of the KEYNOTE-006 trial reported in The Lancet Oncology, Caroline Robert, MD, PhD, and colleagues found that pembrolizumab maintained overall and progression-free survival benefits over ipilimumab in patients with advanced melanoma. In the primary analysis from the...
Cancer Research Institute Names New ‘STARs’ of Cancer Immunotherapy Research
The Cancer Research Institute (CRI), a nonprofit organization dedicated to the discovery and development of immunotherapies for all types of cancer, recently unveiled the inaugural cohort of scientists chosen for the CRI Lloyd J. Old STAR Program (Scientists Taking Risks). Each “STAR” will receive...
A Clinical Trial Was the Right Choice for Me
I found my cancer quite accidentally. In March 2018, as I was taking a shower, my hand casually brushed against my right mastoid bone, and I noticed the area sounded hollow. Around the same time, I realized I had developed a sense of fullness in that ear as well. I had been feeling tired, but that...
Pexidartinib for Tenosynovial Giant Cell Tumor
On August 2, the oral colony-stimulating factor 1 receptor inhibitor pexidartinib was approved for treatment of adult patients with symptomatic tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to improvement with surgery.1,2 It is the first...
USPSTF Recommendation Against Pancreatic Cancer Screening in Asymptomatic Adults
This week, we review the U.S. Preventive Services Task Force (USPSTF) recommendation against screening for pancreatic cancer in adults with no symptoms. We also talk about the discovery of a germline mutation that has been newly associated with pancreatic cancer. Lastly, we discuss a U.S. Food and...
ASTRO Elects Four New Officers to Board of Directors
The members of the American Society for Radiation Oncology (ASTRO) have elected four new officers to ASTRO’s Board of Directors. Laura Dawson, MD, FASTRO, will begin her term as President-Elect in September during ASTRO’s 61st Annual Meeting in Chicago. Neha Vapiwala, MD, was elected as ASTRO’s new ...
Healthy Lifestyle for Young Adult Cancer Survivors
GUEST EDITOR Integrative Oncology is guest edited by Jun J. Mao, MD, MSCE, Laurance S. Rockefeller Chair in Integrative Medicine and Chief of Integrative Medicine Service at Memorial Sloan Kettering Cancer Center, New York. The survival rates of adolescent and young adults with cancer have risen ...
Almost 20 Years Later, Breast Fitness Is More Relevant Than Ever
BOOKMARK Title: Breast Fitness: An Optimal Exercise and Health Plan for Reducing Your Risk of Breast CancerAuthors: Anne McTiernan, MD, PhD; Julie Gralow, MD; and Lisa TalbottPublisher: St. Martin’s PressPublication Date: October 2000 (first edition)Price: $48.75, hardcover, 352 pages The...
MMRF Launches CureCloud to Advance Precision Medicine
The Multiple Myeloma Research Foundation (MMRF) announced recently that it is launching the MMRF CureCloud, a centralized data hub that generates, aggregates, and visualizes data to accelerate the delivery of precision medicine to patients with multiple myeloma. The CureCloud is a critical part of...
Cholangiocarcinoma Foundation Awards $365K in Research Fellowship Grants
The Cholangiocarcinoma Foundation (CCF), a nonprofit organization funding novel research for bile duct cancer, has awarded the fifth cycle of its Research Fellowship Program, in which it will support seven projects for a total of $365,000 in its largest funding cycle to date. Since 2015, the...
MORE Health Collaborates With Memorial Sloan Kettering
MORE Health, a global health-care company, recently announced a strategic collaboration with Memorial Sloan Kettering Cancer Center (MSK) that gives patients from around the world access to the physicians and services of MSK through MORE Health’s Physician Collaboration Platform. MORE Health,...
George J. Bosl, MD, FASCO, MACP, Named Memorial Sloan Kettering’s First Ombudsperson
In July, George J. Bosl, MD, FASCO, MACP, became Memorial Sloan Kettering’s (MSK) first ombudsperson, working closely with staff to provide confidential, independent guidance on complex and evolving issues, particularly related to conflicts of interest. The role of ombudsperson is a result of the...
V. Craig Jordan, CMG, OBE, PhD, DSc, Honored for Accomplishments in Women’s Health
The Companion of the Most Distinguished order of St. Michael and St. George (CMG) is generally reserved for ambassadors and leaders of the United Kingdom’s defense and security services. Only 1, 750 appointees are permitted. This year, the Head of M16, the Secret Intelligence Service, was in the...
FDA Approves Pembrolizumab for Some Patients With PD-L1–Positive Esophageal Cancer
On July 30, the U.S. Food and Drug Administration (FDA) approved the programmed cell death protein 1 inhibitor pembrolizumab (Keytruda) as monotherapy for the treatment of patients with recurrent locally advanced or metastatic esophageal cancer whose tumors express programmed cell death ligand 1...
Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma
In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...
Oral Antibiotics and Risk of Colon or Rectal Cancer
In an extensive data mining analysis of British medical records, researchers found that taking even a single course of antibiotics might boost—albeit slightly—the risk of developing colon cancer, but not rectal cancer, a decade later. The findings, reported by Zhang et al in Gut,...
Impact of Genes on Total Number and Type of Nevi
A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer. “The goal was to investigate the genetic underpinnings of different mole classes, or...
Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...
USPSTF Recommendation on Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer
As reported in JAMA, the U.S. Preventive Services Task Force (USPSTF) recommended risk assessment and, if indicated, genetic counseling and testing for potentially harmful BRCA1/2 mutations in women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer or who have...
What Causes Liver Injury During Treatment With Pembrolizumab
Immunotherapy as a treatment for advanced solid cancers has rapidly evolved over the past decade—often yielding remarkable results. However, its use has also given way to new adverse effects, including drug-induced gastrointestinal and liver toxicities. “Checkpoint inhibitors are a game changer...
An Early Decision to Become an Oncologist
GUEST EDITOR Dr. Abraham is the Director of the Breast Oncology Program at Taussig Cancer Institute, and Professor of Medicine, Lerner College of Medicine, Cleveland Clinic. For this installment of the Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with Gilberto de Lima...
West Virginia University Cancer Institute Welcomes Eight New Doctors
The West Virginia University (WVU) Cancer Institute continues to expand its list of specialists with the addition of eight new doctors. Sonikpreet Aulakh, MD, will join WVU Medicine from Mayo Clinic Florida, where she is completing a hematology oncology fellowship. She completed her medical degree...
Atezolizumab Plus Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Lung Cancer
In late 2018, atezolizumab was approved for use in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberration.1,2 Supporting Efficacy Data Approval was ...
